Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 113 of 6351
-
Can a vaccine stop stomach cancer from coming back?
Cure OngoingThe purpose of this early proof-of-concept study to evaluate the safety and immunologic efficacy of AST-301 in gastric cancer patients with HER2 expression (including both HER2 low expression and overexpression) who have completed the standard adjuvant treatment (including those …
Phase 2 • Sponsor: Aston Sci. Inc. • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
Double immune punch: new combo trial for tough lung cancer
Disease control OngoingThis study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced…
Phase 2/3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Stomach flu vaccine shows promise in massive Kids' trial
Vaccine CompletedThe purpose of this study is to evaluate the Efficacy, Safety and Immunogenicity of the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula polymorpha) in Healthy People Aged 6 Months to 13 Years After Vaccination
Phase 3 • Sponsor: National Vaccine and Serum Institute, China • Aim: Vaccine
Last updated Jun 27, 2026 08:11 UTC
-
New hope for lung cancer patients: experimental drug aims to extend life after other treatments fail
Disease control OngoingThe goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study w…
Phase 3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
First human trial of Gene-Edited lung cells for rare breathing disorder
Disease control Recruiting nowThe major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophage…
Phase 1/2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Immunotherapy duo aims to boost lung cancer cure rates before surgery
Disease control Recruiting nowIn Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients with resectable, early-stage (stage II to IIIA) no…
Phase 2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug iberdomide takes on lenalidomide in battle to keep myeloma at bay
Disease control OngoingThe purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy aims to beat back aggressive breast cancer
Disease control Recruiting nowThis is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer, basal-like/Immune suppressed subtype.
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Gene therapy trial aims to help girls with rett syndrome gain new skills
Disease control OngoingThis study will evaluate the efficacy and safety profiles of the investigational gene therapy, NGN-401, in females with typical Rett syndrome.
Phase 3 • Sponsor: Neurogene Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Stem cell therapy offers hope for children with butterfly skin
Disease control OngoingThe aim of this clinical trial is to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with recessive dystrophic epidermolysis bullosa (RDEB) compared to placebo. An additional baseline-controlled open-label arm will be included to invest…
Phase 3 • Sponsor: RHEACELL GmbH & Co. KG • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for Hard-to-Treat breast cancer: Head-to-Head drug trial launches
Disease control Recruiting nowThis is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (H…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New combo aims to boost lymphoma control in older patients
Disease control Recruiting nowThe goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aims to answer is whether progression free survival kann be prolonged with the addition of Acalabrutinib. Participants will be random…
Phase 3 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
AI-Powered blood test could spot colon cancer before it spreads
Diagnosis Recruiting nowThis is a prospective, multicenter, case-control study. The aim is to develop an optimized algorithm by combining the levels of molecular markers in plasma together with risk factors for developing colorectal cancer and clinical data of patients diagnosed with CRC or AA and healt…
Sponsor: ADVANCED MARKER DISCOVERY S.L. • Aim: Diagnosis
Last updated Jun 27, 2026 07:52 UTC
-
Radioactive 'Smart Bomb' targets melanoma in first human test
Disease control Recruiting nowIn this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectab…
Phase 1/2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Ecstasy-Assisted therapy shows promise for veterans haunted by war
Disease control Recruiting nowThe overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of methylenedioxymethamphetaminel, in participants with Post traumatic Stress Disorder and moral i…
Phase 2 • Sponsor: HaEmek Medical Center, Israel • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Gene therapy breakthrough? new trial targets duchenne muscular dystrophy
Disease control OngoingThe study will evaluate the safety and efficacy of delandistrogene moxeparvovec gene transfer therapy in non-ambulatory and ambulatory males with DMD. This is a randomized, double-blind, placebo-controlled 2-part study. Participants will be in the study for approximately 128 week…
Phase 3 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Heated chemo during surgery could extend lives in ovarian cancer
Disease control Recruiting nowPrimary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)
Phase 3 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for tough lung cancer: tarlatamab takes on relapsed SCLC
Disease control OngoingThe main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New weekly shot could help severely obese heart patients shed pounds
Disease control CompletedThe main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug duo shows promise against aggressive colon cancer
Disease control OngoingEvaluate efficacy and safety of IBI310 (CTLA-4 antibody) in combination with Sintilimab, for neoadjuvant treatment of MSI-H/dMMR resectable colon cancer
Phase 3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC